MicroRNA-495 Regulates Migration and Invasion in Prostate Cancer Cells Via Targeting Akt and mTOR Signaling

References

• Wallace TJ, Torre T, Grob M, Yu J, Avital I, Brucher B, et al. Current approaches, challenges and future directions for monitoring treatment response in prostate cancer. J Cancer 2014;5:3–24.
   PubMed Web of Science ®Google Scholar
• Oh SJ, Erb HH, Hobisch A, Santer FR, Culig Z. Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways. Endocr Relat Cancer 2012;19:305–319.
   PubMed Web of Science ®Google Scholar
• Vishnu P, Tan WW. Update on options for treatment of metastatic castration-resistant prostate cancer. Onco Targets Ther 2010;3:39–51.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281–297.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136:215–233.
   PubMed Web of Science ®Google Scholar
• Kwak PB, Iwasaki S, Tomari Y. The microRNA pathway and cancer. Cancer Sci 2010;101:2309–2315.
   PubMed Web of Science ®Google Scholar
• Liu C, Zhang L, Huang Y, Lu K, Tao T, Chen S, et al. MicroRNA328 directly targets p21activated protein kinase 6 inhibiting prostate cancer proliferation and enhancing docetaxel sensitivity. Mol Med Rep 2015;12:7389–7395.
   PubMed Web of Science ®Google Scholar
• Kurozumi A, Goto Y, Matsushita R, Fukumoto I, Kato M, Nishikawa R, et al. Tumor-suppressive microRNA-223 inhibits cancer cell migration and invasion by targeting ITGA3/ITGB1 signaling in prostate cancer. Cancer Sci 2016;107:84–94.
   Google Scholar
• Wang L, Song G, Tan W, Qi M, Zhang L, Chan J, et al. miR-573 inhibits prostate cancer metastasis by regulating epithelial-mesenchymal transition. Oncotarget 2015;6:35978–90.
   Google Scholar
• Ramalinga M, Roy A, Srivastava A, Bhattarai A, Harish V, Suy S, et al. MicroRNA-212 negatively regulates starvation induced autophagy in prostate cancer cells by inhibiting SIRT1 and is a modulator of angiogenesis and cellular senescence. Oncotarget 2015;6:34446–57.
   Google Scholar
• Gu Y, Lei D, Qin X, Chen P, Zou YM, Hu Y. Integrated analysis reveals together miR-182, miR-200c and miR-221 can help in the diagnosis of prostate cancer. PLoS One 2015;10:e0140862.
   Google Scholar
• Miyazaki T, Ikeda K, Sato W, Horie-Inoue K, Okamoto K, Inoue S. MicroRNA library-based functional screening identified androgen-sensitive miR-216a as a player in bicalutamide resistance in prostate cancer. J Clin Med 2015;4:1853–1865.
   PubMed Web of Science ®Google Scholar
• Li ZJ, Lee A, Huang M, Chun H, Chung J, Chu P, et al. Imaging survival and function of transplanted cardiac resident stem cells. J. Am. Coll. Cardiol. 2009;53:1229–1240.
   PubMed Web of Science ®Google Scholar
• Vo BT, Morton D, Jr., Komaragiri S, Millena AC, Leath C, Khan SA. TGF-beta effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K/AKT/mTOR pathway. Endocrinol. 2013;154:1768–1779.
   PubMed Web of Science ®Google Scholar
• Ni J, Cozzi P, Hao J, Beretov J, Chang L, Duan W, et al. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway. Int J Biochem Cell Biol 2013;45:2736–2748.
   PubMed Web of Science ®Google Scholar
• Chang L, Graham PH, Hao J, Bucci J, Cozzi PJ, Kearsley JH, et al. Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy. Cancer Metastasis Rev 2014;33:469–496.
   PubMed Web of Science ®Google Scholar
• Chang L, Graham PH, Hao J, Ni J, Bucci J, Cozzi PJ, et al. PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways. Cell Death Dis 2014;5:e1437.
   PubMed Web of Science ®Google Scholar
• Chen SM, Chen HC, Chen SJ, Huang CY, Chen PY, Wu TW, et al. MicroRNA-495 inhibits proliferation of glioblastoma multiforme cells by downregulating cyclin-dependent kinase 6. World J Surg Oncol 2013;11:87.
   PubMed Web of Science ®Google Scholar
• Xu YY, Tian J, Hao Q, Yin LR. MicroRNA-495 downregulates FOXC1 expression to suppress cell growth and migration in endometrial cancer. Tumour Biol 2015. DOI:10.1007/s13277-015-3686-6
   Google Scholar
• Ai C, Jiang R, Fu L, Chen Y. MicroRNA-495 mimics delivery inhibits lung tumor progression. Tumour Biol 2015;36:729–735.
   PubMed Web of Science ®Google Scholar
• Cao M, Nie W, Li J, Zhang Y, Yan X, Guan X, et al. MicroRNA-495 induces breast cancer cell migration by targeting JAM-A. Protein Cell 2014;5:862–872.
   PubMed Web of Science ®Google Scholar
• Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 2008;8:393–412.
   PubMed Web of Science ®Google Scholar
• Yang XL, Lin FJ, Guo YJ, Shao ZM, Ou ZL. Gemcitabine resistance in breast cancer cells regulated by PI3K/AKT-mediated cellular proliferation exerts negative feedback via the MEK/MAPK and mTOR pathways. Onco Targets Ther 2014;7:1033–1042.
   PubMed Web of Science ®Google Scholar
• Lin VC, Kuo PT, Lin YC, Chen Y, Hseu YC, Yang HL, et al. Penta-O-galloyl-beta-D-glucose suppresses EGF-induced eIF3i expression through inhibition of the PI3K/AKT/mTOR pathway in prostate cancer cells. J Agric Food Chem 2014;62:8990–8996.
   PubMed Web of Science ®Google Scholar
• Yu P, Ye L, Wang H, Du G, Zhang J, Zhang J, et al. NSK-01105 inhibits proliferation and induces apoptosis of prostate cancer cells by blocking the Raf/MEK/ERK and PI3K/Akt/mTOR signal pathways. Tumour Biol 2014;36:2143–53.
   Google Scholar